About Galapagos Genomics
Developer of a functional genomics platform that consists of the construction and screening of adenoviral knock-in and knock-down libraries for the discovery and validation of novel drug targets and therapeutic genes. The screening of the libraries is performed in human cell-based and phenotypic functional assays. Both the construction and the screening of the libraries are set up in a high-throughput, automated and arrayed format. The phenotypic selection libraries are used both for internal discovery activities as well as in collaboration agreements with partners. The company is focused on the rapid identification and validation of disease modifying drug targets by functional screening in human disease models. Research activities encompass the internal programs in osteoporosis, rheumatoid arthritis, osteoarthritis, and Alzheimer's disease, as well as partnerships with pharmaceutical, nutraceutical, and biotech companies. Proprietary targets resulting from internal programs are used for the development of drugs in core disease areas, combined with selected out-licensing and partnering of projects during development.